Search

Your search keyword '"Chiang, Derek"' showing total 61 results

Search Constraints

Start Over You searched for: Author "Chiang, Derek" Remove constraint Author: "Chiang, Derek" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
61 results on '"Chiang, Derek"'

Search Results

1. Data from ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells

2. Supplementary Figures 1- 7 from ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells

3. Supplementary figures from Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes

4. Supplementary Figures 1- 7 from ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells

5. Supplementary Tables 1-4 from ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells

6. Supplementary Materials and Methods and Supplementary Figure Legends 1-7 from ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells

7. Data from Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes

8. Data from Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes

9. Supplementary tables from Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes

10. Supplementary figures from Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes

11. Supplementary Materials and Methods and Supplementary Figure Legends 1-7 from ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells

12. Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models

13. Supplementary tables from Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes

14. Supplementary Tables 1-4 from ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells

15. Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models

16. Data from ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells

17. Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models

18. Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models

19. Supplementary Data from EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

20. Supplementary Data from EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

21. Supplementary Information from Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma

22. Data from Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma

23. Data from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

24. Supplementary Figure 5 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

25. Supplementary Figure 6 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

26. Supplementary Figure 2 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

27. Supplementary Figure 5 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

28. Data from Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma

29. Data from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

30. Supplementary Figure 2 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

31. Data from Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma

32. Supplementary Figure 4 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

33. Supplementary Table 1 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

34. Supplementary Figure 4 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

35. Supplementary Figure 3 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

36. Supplementary Methods, Table Legend, Figure Legends 1-6 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

37. Data from Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma

38. Supplementary Figure 3 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

39. Supplementary Figure 1 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

40. Supplementary Figure 6 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

41. Supplementary Information from Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma

42. Supplementary Table 1 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

43. Supplementary Methods, Table Legend, Figure Legends 1-6 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

44. Supplementary Figure 1 from Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies

45. Abstract 3588: Discovery of potent and selective CSNK1A1 inhibitors for solid tumor therapy

46. Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models

47. ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells

49. Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes

50. Abstract B36: Modeling genetic mechanisms of resistance in melanoma primary tumor xenografts

Catalog

Books, media, physical & digital resources